AP2001002181A0 - Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses. - Google Patents

Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.

Info

Publication number
AP2001002181A0
AP2001002181A0 APAP/P/2001/002181A AP2001002181A AP2001002181A0 AP 2001002181 A0 AP2001002181 A0 AP 2001002181A0 AP 2001002181 A AP2001002181 A AP 2001002181A AP 2001002181 A0 AP2001002181 A0 AP 2001002181A0
Authority
AP
ARIPO
Prior art keywords
virus
compounds
hepatitis
treatment
metabolites
Prior art date
Application number
APAP/P/2001/002181A
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Patrick T Prendergast
Original Assignee
Hollis Eden Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals Inc filed Critical Hollis Eden Pharmaceuticals Inc
Publication of AP2001002181A0 publication Critical patent/AP2001002181A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention provides the use of 17-ketosteroid compounds, as well as derivatives, metabolites and precursors of such compounds, and pharmaceutically acceptable salts of any of these compounds, collectively defined herein as the "compounds of the present invention", in the treatment of prevention of hepatitis C type virus and/or hepatitis G type virus in patients in need of such treatment. in addition, the invention provides methods to treat or prevent togavirus infections, including infections by one or more alphaviruses, flaviviruses, such as yellow fever virus, hepatitis C virus and hepatitis G virus, rubella viruses, or pestiviruses, such as bovine virus diarrhea virus. In addition, the invention provides combination therapies including administration of one or more compound selected from plasma concentration-enhancing compounds, macrophage stimulating factor, oxidation agents, ribavirin and alpha interferon, and/or oxygen ventilation. The compounds of the present invention may also be used to ameliorate or reduce one or more symptoms associated with a togavirus infection.
APAP/P/2001/002181A 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses. AP2001002181A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10992498P 1998-11-24 1998-11-24
US12408799P 1999-03-11 1999-03-11
US12605699P 1999-03-23 1999-03-23
PCT/US1999/028082 WO2000032177A2 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections

Publications (1)

Publication Number Publication Date
AP2001002181A0 true AP2001002181A0 (en) 2001-05-24

Family

ID=27380740

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002181A AP2001002181A0 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.

Country Status (14)

Country Link
EP (1) EP1133287A2 (en)
JP (1) JP2002531397A (en)
KR (1) KR20010101074A (en)
CN (1) CN1328463A (en)
AP (1) AP2001002181A0 (en)
AU (1) AU775614B2 (en)
BR (1) BR9915644A (en)
CA (1) CA2352205A1 (en)
HK (1) HK1042426A1 (en)
ID (1) ID29864A (en)
IL (2) IL142942A0 (en)
NZ (1) NZ511721A (en)
OA (1) OA11716A (en)
WO (1) WO2000032177A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US6555523B1 (en) 1999-07-08 2003-04-29 Patrick T. Prendergast Use of cirsiliol and derivatives to treat infections
DK1955700T3 (en) 1999-09-30 2011-05-23 Harbor Biosciences Inc Therapeutic treatment of androgen receptor-related disorders
EP1534299A4 (en) * 2002-07-02 2007-04-11 Corcept Therapeutics Inc Methods for treating psychosis associated with interferon-alpha therapy
CA2496867A1 (en) * 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
PL2219642T3 (en) 2007-11-15 2012-02-29 Madaus Gmbh Silibinin component for the treatment of hepatitis
CN102993148B (en) * 2011-09-13 2015-12-09 复旦大学 Quercetin derivative or its analogue and application thereof
WO2013178782A1 (en) * 2012-05-30 2013-12-05 Universidad De Zaragoza Allosteric inhibitors of ns3 protease from hepatitis c virus
CN108003212A (en) * 2017-12-24 2018-05-08 扬州工业职业技术学院 A kind of dehydroepiandros-sterone -6- glucoside derivatives and its application as anti hepatitis C virus drug
CN110452280B (en) * 2019-07-25 2020-11-17 中国人民解放军第二军医大学 Tetracyclic triterpenic acid derivative and preparation method and application thereof
JP2023543352A (en) * 2020-09-22 2023-10-13 マイクロナイゼーション テクノロジーズ アンド セラピューティクス グループ エルエルシー Nebulizers and atomized antivirals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (en) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Pharmaceutical preparation suitable for the prophylaxis or therapy of a retroviral infection or a complication or consequence thereof.
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
CN1216470A (en) * 1996-04-17 1999-05-12 帕特里克·T·普伦德加斯特 DHEA combination therapy
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors

Also Published As

Publication number Publication date
IL142942A (en) 2006-08-20
WO2000032177A2 (en) 2000-06-08
BR9915644A (en) 2001-08-07
AU3105200A (en) 2000-06-19
CA2352205A1 (en) 2000-06-08
KR20010101074A (en) 2001-11-14
HK1042426A1 (en) 2002-08-16
OA11716A (en) 2005-01-25
EP1133287A2 (en) 2001-09-19
AU775614B2 (en) 2004-08-05
NZ511721A (en) 2004-07-30
ID29864A (en) 2001-10-18
IL142942A0 (en) 2002-04-21
JP2002531397A (en) 2002-09-24
WO2000032177A3 (en) 2001-03-22
CN1328463A (en) 2001-12-26

Similar Documents

Publication Publication Date Title
MXPA02012443A (en) 3 -PRODRUGS OF 2 -DEOXY-bgr;-L-NUCLEOSIDES.
RS114104A (en) 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
HK1068538A1 (en) Antiviral compounds
RS114004A (en) Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
AU2002360592A8 (en) Inhibitors of hepatitis c virus
AP1727A (en) Methods and compositions for treating flaviviruses and pestiviruses.
RS113904A (en) 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
UY26724A1 (en) METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUSES
AP2001002181A0 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.
MD940152A (en) Pharmaceutical composition for the treatment of infections and diseases caused by Hepatitis B Virus (HBV)
MY125300A (en) Synergistic combination for treatment of viral-mediated diseases
SG165996A1 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
DE60125377D1 (en) TREATMENT OF HEPATITIS C WITH THYMOSINE, INTERFERON AND RIBAVIRIN
UA31078A (en) HUMAN IMMUNODEFICIENCY VIRUS INHIBITOR (DARIMID)